--- a
+++ b/clusters/9knumclustersv2/clust_1507.txt
@@ -0,0 +1,56 @@
+Histologically confirmed locally advanced gastric (primary endpoint includes proximal and mid-body stomach) or esophagogastric adenocarcinoma; distal gastric (antral) adenocarcinomas are eligible for enrollment but will not be included in the primary analysis
+History of gastric or small bowel surgery involving any extent of gastric or small bowel resection.
+Squamous cell or undifferentiated gastric cancer
+Gastric carcinoma.
+Gastric bypass
+Symptomatic evidence of gastric outlet obstruction
+Uncontrolled or active gastric or duodenal ulcer disease within  days of enrollment
+Active inflammatory gastrointestinal disease or previous gastric resection or lap band
+Advanced Gastric Cancer
+History of gastrointestinal mal-absorption or gastric bypass surgery
+Have a history of gastric bypass surgery or severe malabsorption that may interfere with the absorption of the study agents
+Metastatic or relapsed Gastric cancer (adenocarcinoma) (module )
+Presence of duodenal or gastric invasion by the tumor as noted by esophagogastroduodenoscopy (EGD) at time of fiducial placement
+Evidence of gross duodenal invasion, gastric outlet obstruction
+History of gastric or duodenal ulcers or untreated hyperacidity syndromes
+Symptomatic evidence of gastric outlet obstruction
+Subject has gastric outlet syndrome or persistent/recurrent vomiting.
+Subject with recent gastric bleeding or symptomatic subjects with proven gastric ulcers that would exclude the subject from participation.
+Must have operable gastric adenocarcinoma, T-Ta, N-N, M
+History of gastric or small bowel surgery.
+History of gastric or small bowel surgery involving any extent of gastric or small bowel resection.
+Her- positive gastric tumor
+No uncontrolled gastric ulcer disease (grade  gastric ulcer disease) within  days of registration
+Subjects (NSCLC and gastric adenocarcinoma) must be determined to have HA-high levels from their tumor biopsies.
+Gastric adenocarcinoma subjects with brain metastases
+Squamous cell or undifferentiated gastric cancer
+Phase  expansion: Gastric Cancer
+Gastric Cancer
+Diagnosis of squamous or undifferentiated gastric cancer
+Malabsorption, total gastric resection
+Participant has active, high risk bleeding (such as, via gastric ulcers or gastric varices) within  days prior to randomization
+The participant has squamous cell or undifferentiated gastric cancer.
+Squamous cell or undifferentiated gastric cancer
+Active uncontrolled gastric or duodenal ulcer
+Gastric or duodenal ulcer (at least  mm in size) within  mm of expected endoscopy puncture site(s) for photodynamic therapy (PDT)
+Gastric cancer (including gastric and EGJ cancers): at least  prior systemic regimens in adjuvant, advanced, or metastatic setting and, as appropriate, a human epidermal growth factor receptor  (HER) targeted agent.
+More than one prior line of therapy for advanced gastric cancer
+For subjects with gastric cancer:
+Prior gastric surgery, small bowel resection, or other conditions that may impede adequate absorption of oral study drug
+Patients with clinical bleeding, active gastric, or duodenal ulcer
+Impaired gastrointestinal (GI) function such as from significant small bowel resection or gastric bypass surgery or inability to swallow up to five ceritinib capsules daily
+Patients who have a history of previous gastric or duodenal surgery
+A history of gastric or duodenal ulcers or hyperacidity syndromes
+Delayed gastric emptying syndrome
+Patients must not have documented history of gastric/duodenal ulcer within the last  months; participant must not currently be on treatment for gastric/duodenal ulcer or be experiencing symptoms at study entry; patients with gastroesophageal reflux disease (GERD) are eligible, however, and these patients may receive over-the-counter histamine- (H) antagonists; proton-pump inhibitors, or other prescription-based treatment for GERD
+History of gastric ulcer within the past  years (with or without bleeding)
+Individuals with prior gastric bypass surgery or procedure that would impair absorption of nutrients
+History of gastric surgery
+Patients with a history of gastric bypass surgery
+Individual with history of gastric bypass due to any reason
+Gastric paresis
+History of gastric ulcer within the past  years (with or without bleeding)
+Active inflammatory gastrointestinal disease or previous gastric resection or lap band
+History of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect gastric absorption
+Gastric bypass
+History of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect the absorption of kava